Warning -Patient Observation & Monitoring for Erbitux(Jan06)
Pharmacy
|
-
Currently 0.00/5
- 1
- 2
- 3
- 4
- 5
Rating: 0.0 out of 0 votes
Comments (0)
|
You need to have the
Flash Player installed and
a browser with JavaScript support.
Description
ImClone Systems and Bristol-Myers Squibb have notified healthcare professionals about new safety information for the drug Erbitux (cetuximab). Erbitux is used to treat certain patients with EGFR-expressing metastatic colorectal cancer. The product labeling had already warned about the risk of severe infusion reactions in patients being treated with Erbitux. The labeling now warns that patients should be observed for one hour following Erbitux infusion because of this risk. Patients who do experience infusion reactions may need to be observed for more than one hour. Patients being treated with Erbitux are also at increased risk for electrolyte abnormalities. So they should be monitored periodically for hypomagnesemia, and accompanying hypocalcemia and hypokalemia, both during therapy and after therapy is completed.
|
Tags
|
Sign in or sign up to post comments.